- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Results of the ECOG E3805 Study
Michael J. Morris, MD, GU Oncologists, Memorial Sloan Kettering Cancer Center, discusses the results of the ECOG E3805 study, which examined chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer.
Michael J. Morris, MD, GU Oncologists, Memorial Sloan Kettering Cancer Center, discusses the results of the ECOG E3805 study, which examined chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer.
Clinical Pearls:
- Patients in this trial were randomized to receive hormone therapy alone or hormone therapy plus 6 cycles of docetaxel.
- Median OS was 57.6 months in the hormone therapy plus docetaxel arm and 44.0 months in the hormone therapy arm.
- Median time to clinical progression was greater in the docetaxel plus hormone therapy arm (32.7 months) than the hormone therapy-only arm (19.8 months).
<<<